237 related articles for article (PubMed ID: 24166472)
1. KCa3.1 mediates activation of fibroblasts in diabetic renal interstitial fibrosis.
Huang C; Shen S; Ma Q; Gill A; Pollock CA; Chen XM
Nephrol Dial Transplant; 2014 Feb; 29(2):313-24. PubMed ID: 24166472
[TBL] [Abstract][Full Text] [Related]
2. Blockade of KCa3.1 ameliorates renal fibrosis through the TGF-β1/Smad pathway in diabetic mice.
Huang C; Shen S; Ma Q; Chen J; Gill A; Pollock CA; Chen XM
Diabetes; 2013 Aug; 62(8):2923-34. PubMed ID: 23656889
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of KCa3.1 suppresses TGF-β1 induced MCP-1 expression in human proximal tubular cells through Smad3, p38 and ERK1/2 signaling pathways.
Huang C; Day ML; Poronnik P; Pollock CA; Chen XM
Int J Biochem Cell Biol; 2014 Feb; 47():1-10. PubMed ID: 24291552
[TBL] [Abstract][Full Text] [Related]
4. Blockade of KCa3.1: A novel target to treat TGF-β1 induced conjunctival fibrosis.
Anumanthan G; Wilson PJ; Tripathi R; Hesemann NP; Mohan RR
Exp Eye Res; 2018 Feb; 167():140-144. PubMed ID: 29242028
[TBL] [Abstract][Full Text] [Related]
5. High glucose induces CCL20 in proximal tubular cells via activation of the KCa3.1 channel.
Huang C; Pollock CA; Chen XM
PLoS One; 2014; 9(4):e95173. PubMed ID: 24733189
[TBL] [Abstract][Full Text] [Related]
6. KCa3.1 mediates dysfunction of tubular autophagy in diabetic kidneys via PI3k/Akt/mTOR signaling pathways.
Huang C; Lin MZ; Cheng D; Braet F; Pollock CA; Chen XM
Sci Rep; 2016 Mar; 6():23884. PubMed ID: 27029904
[TBL] [Abstract][Full Text] [Related]
7. The KCa3.1 blocker TRAM34 reverses renal damage in a mouse model of established diabetic nephropathy.
Huang C; Zhang L; Shi Y; Yi H; Zhao Y; Chen J; Pollock CA; Chen XM
PLoS One; 2018; 13(2):e0192800. PubMed ID: 29425253
[TBL] [Abstract][Full Text] [Related]
8. KCa3.1 ion channel: A novel therapeutic target for corneal fibrosis.
Anumanthan G; Gupta S; Fink MK; Hesemann NP; Bowles DK; McDaniel LM; Muhammad M; Mohan RR
PLoS One; 2018; 13(3):e0192145. PubMed ID: 29554088
[TBL] [Abstract][Full Text] [Related]
9. The KCa3.1 blocker TRAM-34 inhibits proliferation of fibroblasts in paraquat-induced pulmonary fibrosis.
Xie H; Lu J; Zhu Y; Meng X; Wang R
Toxicol Lett; 2018 Oct; 295():408-415. PubMed ID: 30036685
[TBL] [Abstract][Full Text] [Related]
10. K⁺-channel inhibition reduces portal perfusion pressure in fibrotic rats and fibrosis associated characteristics of hepatic stellate cells.
Freise C; Heldwein S; Erben U; Hoyer J; Köhler R; Jöhrens K; Patsenker E; Ruehl M; Seehofer D; Stickel F; Somasundaram R
Liver Int; 2015 Apr; 35(4):1244-52. PubMed ID: 25212242
[TBL] [Abstract][Full Text] [Related]
11. Renal fibrosis is attenuated by targeted disruption of KCa3.1 potassium channels.
Grgic I; Kiss E; Kaistha BP; Busch C; Kloss M; Sautter J; Müller A; Kaistha A; Schmidt C; Raman G; Wulff H; Strutz F; Gröne HJ; Köhler R; Hoyer J
Proc Natl Acad Sci U S A; 2009 Aug; 106(34):14518-23. PubMed ID: 19706538
[TBL] [Abstract][Full Text] [Related]
12. Gal-3 (Galectin-3) and K
She G; Hou MC; Zhang Y; Zhang Y; Wang Y; Wang HF; Lai BC; Zhao WB; Du XJ; Deng XL
Hypertension; 2020 Feb; 75(2):393-404. PubMed ID: 31838908
[TBL] [Abstract][Full Text] [Related]
13. FSP1-specific SMAD2 knockout in renal tubular, endothelial, and interstitial cells reduces fibrosis and epithelial-to-mesenchymal transition in murine STZ-induced diabetic nephropathy.
Loeffler I; Liebisch M; Allert S; Kunisch E; Kinne RW; Wolf G
Cell Tissue Res; 2018 Apr; 372(1):115-133. PubMed ID: 29209813
[TBL] [Abstract][Full Text] [Related]
14. Blockade of KCa3.1 Attenuates Left Ventricular Remodeling after Experimental Myocardial Infarction.
Ju CH; Wang XP; Gao CY; Zhang SX; Ma XH; Liu C
Cell Physiol Biochem; 2015; 36(4):1305-15. PubMed ID: 26160442
[TBL] [Abstract][Full Text] [Related]
15. Klotho attenuates high glucose-induced fibronectin and cell hypertrophy via the ERK1/2-p38 kinase signaling pathway in renal interstitial fibroblasts.
Huang JS; Chuang CT; Liu MH; Lin SH; Guh JY; Chuang LY
Mol Cell Endocrinol; 2014 Jun; 390(1-2):45-53. PubMed ID: 24721634
[TBL] [Abstract][Full Text] [Related]
16. Targeted inhibition of KCa3.1 attenuates TGF-β-induced reactive astrogliosis through the Smad2/3 signaling pathway.
Yu Z; Yu P; Chen H; Geller HM
J Neurochem; 2014 Jul; 130(1):41-49. PubMed ID: 24606313
[TBL] [Abstract][Full Text] [Related]
17. KCa3.1: a new player in progressive kidney disease.
Huang C; Pollock CA; Chen XM
Curr Opin Nephrol Hypertens; 2015 Jan; 24(1):61-6. PubMed ID: 25415613
[TBL] [Abstract][Full Text] [Related]
18. Role of the potassium channel KCa3.1 in diabetic nephropathy.
Huang C; Pollock CA; Chen XM
Clin Sci (Lond); 2014 Oct; 127(7):423-33. PubMed ID: 24963668
[TBL] [Abstract][Full Text] [Related]
19. Resveratrol inhibits renal interstitial fibrosis in diabetic nephropathy by regulating AMPK/NOX4/ROS pathway.
He T; Xiong J; Nie L; Yu Y; Guan X; Xu X; Xiao T; Yang K; Liu L; Zhang D; Huang Y; Zhang J; Wang J; Sharma K; Zhao J
J Mol Med (Berl); 2016 Dec; 94(12):1359-1371. PubMed ID: 27488452
[TBL] [Abstract][Full Text] [Related]
20. Increased constitutive αSMA and Smad2/3 expression in idiopathic pulmonary fibrosis myofibroblasts is KCa3.1-dependent.
Roach KM; Wulff H; Feghali-Bostwick C; Amrani Y; Bradding P
Respir Res; 2014 Dec; 15(1):155. PubMed ID: 25476248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
